This document discusses risk factors for hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C virus (HCV) infection. It notes that HCV typically leads to chronic infection in over 60% of patients and cirrhosis may develop over 20 years. The risk of HCC increases with cirrhosis development. Factors like alcohol use, HIV/HBV co-infection, and hepatitis B core antibody positivity can further increase HCC risk. Non-invasive screening tools and risk scores are useful to monitor at-risk patients and prioritize them for HCC surveillance.
Liver Fibrosis: Difficulties in Diagnostic and Treatment: A Review-Crimson Pu...CrimsonGastroenterology
Early discovery of liver fibrosis and cirrhosis is becoming more relevant because of enhanced incidence of hepatocellular carcinoma. There a many underlying factors in developing liver fibrosis (i.e. viral hepatitis, steatohepatitis). Diagnosis of liver fibrosis is difficult; chronic liver failure and less distinct fibrosis stages can be underestimated, when laboratory routine parameters and native ultrasound of the liver are unsuspicious. Liver biopsy is a common element of diagnostic workup in hepatic cirrhosis, alongside clinical examination and abdominal ultrasound, and is the accepted diagnostic gold standard. But there is no unitary system of histological classification used to evaluate the degree of fibrosis, and individual systems are often validated only for individual disease entities. On the other hand liver biopsy is of less tolerance for patients. In the last years serological markers for detecting liver fibrosis were developed with different validity. Various imaging modalities have been proposed as methods for assessing liver fibrosis
by liver stiffness measurement. They are sufficient to approve the suspicious of liver fibrosis and/or to uncover unknown chronic liver failure. Studies showed the clinical usefulness of acoustic radiation force impulse shear wave elasticity imaging (ARFI-SWEI) is efficient as a preventive screening method to uncover fibrosis. The ARFI-SWEI system is integrated in an ultrasound device has a good accuracy and high reproducibility. Therapy of liver fibrosis depends on underlying disease and degree of liver failure. When liver failure can be cured liver fibrosis can regress. Direct antifibrotic drugs are
actually not available but in progress.
Liver Fibrosis: Difficulties in Diagnostic and Treatment: A Review-Crimson Pu...CrimsonGastroenterology
Early discovery of liver fibrosis and cirrhosis is becoming more relevant because of enhanced incidence of hepatocellular carcinoma. There a many underlying factors in developing liver fibrosis (i.e. viral hepatitis, steatohepatitis). Diagnosis of liver fibrosis is difficult; chronic liver failure and less distinct fibrosis stages can be underestimated, when laboratory routine parameters and native ultrasound of the liver are unsuspicious. Liver biopsy is a common element of diagnostic workup in hepatic cirrhosis, alongside clinical examination and abdominal ultrasound, and is the accepted diagnostic gold standard. But there is no unitary system of histological classification used to evaluate the degree of fibrosis, and individual systems are often validated only for individual disease entities. On the other hand liver biopsy is of less tolerance for patients. In the last years serological markers for detecting liver fibrosis were developed with different validity. Various imaging modalities have been proposed as methods for assessing liver fibrosis
by liver stiffness measurement. They are sufficient to approve the suspicious of liver fibrosis and/or to uncover unknown chronic liver failure. Studies showed the clinical usefulness of acoustic radiation force impulse shear wave elasticity imaging (ARFI-SWEI) is efficient as a preventive screening method to uncover fibrosis. The ARFI-SWEI system is integrated in an ultrasound device has a good accuracy and high reproducibility. Therapy of liver fibrosis depends on underlying disease and degree of liver failure. When liver failure can be cured liver fibrosis can regress. Direct antifibrotic drugs are
actually not available but in progress.
Tyler Lonergan, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Patients who obtaining hepatitis D infection either as co-infection or super-infection, become chronic hepatitis B infected, which then they can undergoes as active chronic hepatitis B infected or inactive carriers, but hepatitis D infection, remains active and dominates the further deterioration and hepatic injury.
Most of the patients having progressively deteriorating of liver function and increased susceptibility having a liver cirrhosis and even end-stage liver failure .
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, presents with various clinical features that can help diagnose and stage the disease. These features, along with imaging studies and laboratory tests, aid in determining the extent and severity of HCC. Here are the key clinical features and staging considerations:
Clinical Features:
Abdominal Pain: HCC can cause pain or discomfort in the upper right abdomen due to liver enlargement or tumor growth.
Jaundice: Yellowing of the skin and eyes (jaundice) may occur when the tumor affects liver function or obstructs the bile ducts.
Weight Loss: Unintentional weight loss may result from factors such as decreased appetite or cancer-related wasting.
Fatigue and Weakness: HCC patients often experience persistent fatigue and generalized weakness.
Loss of Appetite and Nausea: HCC can lead to reduced appetite, resulting in nausea and vomiting.
Abdominal Swelling: Ascites, the accumulation of fluid in the abdomen, may cause abdominal distension and discomfort.
Enlarged Liver: As HCC progresses, the liver may become palpable due to its enlargement and the presence of a tumor.
Staging: HCC staging helps determine the extent and spread of the cancer, guiding treatment decisions. The most commonly used staging system for HCC is the Barcelona
Tyler Lonergan, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Patients who obtaining hepatitis D infection either as co-infection or super-infection, become chronic hepatitis B infected, which then they can undergoes as active chronic hepatitis B infected or inactive carriers, but hepatitis D infection, remains active and dominates the further deterioration and hepatic injury.
Most of the patients having progressively deteriorating of liver function and increased susceptibility having a liver cirrhosis and even end-stage liver failure .
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, presents with various clinical features that can help diagnose and stage the disease. These features, along with imaging studies and laboratory tests, aid in determining the extent and severity of HCC. Here are the key clinical features and staging considerations:
Clinical Features:
Abdominal Pain: HCC can cause pain or discomfort in the upper right abdomen due to liver enlargement or tumor growth.
Jaundice: Yellowing of the skin and eyes (jaundice) may occur when the tumor affects liver function or obstructs the bile ducts.
Weight Loss: Unintentional weight loss may result from factors such as decreased appetite or cancer-related wasting.
Fatigue and Weakness: HCC patients often experience persistent fatigue and generalized weakness.
Loss of Appetite and Nausea: HCC can lead to reduced appetite, resulting in nausea and vomiting.
Abdominal Swelling: Ascites, the accumulation of fluid in the abdomen, may cause abdominal distension and discomfort.
Enlarged Liver: As HCC progresses, the liver may become palpable due to its enlargement and the presence of a tumor.
Staging: HCC staging helps determine the extent and spread of the cancer, guiding treatment decisions. The most commonly used staging system for HCC is the Barcelona
This lecture is about Spectrum of HCV infection presented by Dr. Muhammad Mostafa Abdel Ghaffar, Head of Tropical Medicine Department, Ahmed Maher Teaching Hospital.
The lecture was presented in the scientific meeting of Internal and Tropical Medicine departments, Ahmed Maher Teaching Hospital titled (Towards Eradication of HCV in Egypt) in celebration of World Hepatitis Day on July 28, 2016.
https://www.facebook.com/AMTH.IM
https://www.facebook.com/events/1072758396145209/
http://www.no4c.com
Presentazione a cura del Dottor Claudio Puoti - "HOT TOPICS IN GASTROENTEROLOGIA - I TUMORI DELL'APPARATO DIGERENTE: cosa è cambiato e cosa bisogna sapere" - Roma 10/11/2018
Background: The precise evaluation of hepatic fi brosis is crucial in the management of Chronic Hepatitis C (CHC). Multiple noninvasive serological scores and devices have been used in the accurate prediction of fibrosis however; early changes in non-invasive
biomarkers of liver fibrosis following antiviral therapy are widely unknown. We aim to evaluate changes of liver stiffness and 6 noninvasive serological fibrosis scores, easy to calculate particularly in poor areas, following sofosbuvir- based treatment.
Methods: This is a cohort study that included 155 CHC Egyptian patients. Transient elastography values were recorded as well
as Aspartate Aminotransferase-To-Platelet Ratio Index (APRI), FIB-4, Lok score, fibrosis index, King Score and fibro Q score were calculated at baseline and 12 weeks post-treatment.
CYPRESS COLLEGE DIVISION OF HEALTH SCIENCE HS 147 Hi.docxwhittemorelucilla
CYPRESS COLLEGE
DIVISION OF HEALTH SCIENCE
HS 147
Hints for writing your final disease report: (not in any order)
1. In your abstract, don't give a history of your disorder. Give the reader a
short synopsis of what the research is going to cover. Don’t forget “key
words”. Research papers are not a "friendly format”, don’t add personal
comments or opinions or slang. Assume this will be printed in a journal.
2. Use 12 point, Geneva style font (or similar) for your paper, with a 1”
margin on all sides.
3. Number your pages in the upper right corner. Your report will be about 7-9
pages not counting the cover page and reference page. Remember to
print the "word count" on cover page (1500 minimum).
4. Do not list or use bullets. Write in complete sentences and paragraphs.
5. Section headings help the reader. Remember to only double space,
even between headings or paragraphs.
6. Don't start a sentence with "according to......". Instead start with the
information and use an in-text citation at the end of the sentence or
paragraph.
7. If you start a sentence with a number, you must write out the number.
8. For your report remember, you are writing as a professional to another
professional and not to a patient or “lay person”. Do not explain things
that you would expect that the reader would already know.
9. Have someone else read your report before you turn it in for grammar,
spelling and punctuations.
10. Do not use a separate page for each section or heading (double space
only).
11. Include the website that the information was retrieved from, not the
search engine the school used (EBSCO). Use the APA format in your
syllabus.
Good luck!
June 15, 2015 ◆ Volume 91, Number 12 www.aafp.org/afp American Family Physician 835
Diagnosis and Management of Hepatitis C
THAD WILKINS, MD; MARIAM AKHTAR, MD; and EUNICE GITITU, MD, Georgia Regents University, Augusta, Georgia
CHRISTINE JALLURI, MD, and JASON RAMIREZ, MD, University of Maryland, Baltimore, Maryland
H
epatitis C virus (HCV) infec-
tion is a major cause of chronic
liver disease and cirrhosis.1
The World Health Organi-
zation reports that there are at least 185
million persons worldwide with the infec-
tion, causing 350,000 deaths annually.1 In
the United States, an estimated 2.7 mil-
lion individuals are chronically infected
with HCV.2 The burden of HCV infection
in the United States is expected to increase
because of the high proportion of persons
who were infected in the 1960s and 1970s.3
In 2013, the total cost of HCV infection in
the United States was estimated at $6.5 bil-
lion.4 Chronic HCV infection leads to sig-
nificantly more lost days of work, decreased
productivity, and increased health care
costs.5 This article focuses on chronic HCV
infection in adults and excludes special
groups, such as children, pregnant women,
transplant recipients, and persons coi.
Report on LUS for post COVID19 Infection Patients, NGUYEN THIEN HUNG et al, M...hungnguyenthien
Report of LUS on 11 patients (5 man and 6 female) underwent COVID-19 infection for average 30 days showed that lung lesions were still existed with small evident and LUS score total <10.
Lung Ultrasound Post-COVID-19 Infection, Hung Nguyen Thien and Ultrasound Dep...hungnguyenthien
11 cases (5 male and 6 female) were post COVID-19 infection, enrolled in LUS with remained lesions in left posterior basal lung than right one. LUS score total < 10 according to protocol of ROUBY.
Evaluation of Hyperferritinemia in Diabetic Patientshungnguyenthien
Hyperferritinemia with normal transferrin saturation, with or without iron overload is often found in patients with hepatic steatosis and/or hepatitis. The metabolic hyperferritinaemia (disorder of iron and glucose and/or lipid metabolism) may occur with the incidence up to 49% in type 2 diabetes mellitus.
A review on of AAA at Medic Center for 10 years (1990-2000), 246/987 cases of AAA dissecting were detected and documented by ultrasound and CT scanning confirmed, # 24.9%, that had been prothesis grafting later in Binh dan hospital.
BIRADS- 5 NON CANCER, Dr Đỗ Bình Minh Dr Hương Gianghungnguyenthien
Một số bệnh lý vú lành tính có hình ảnh học giống ung thư được trình bày gồm sẹo nan hoa (radial scar), bệnh tuyến xơ hóa (sclerosing adenosis), bệnh vú xơ hóa do đái tháo đường (diabetic fibrous breast disease), viêm vú mạn tính gồm hoại tử mỡ (fat necrosis) và lao vú.
CAP va ARFI trong Gan Mỡ , Nguyễn Thiện Hùng, Nguyễn thị Hồng Anh , Phạm thị ...hungnguyenthien
Đối chiếu CAP, Fibroscan,ARFI, và Siêu âm B-Mode trên 84 bệnh nhân gan mỡ không do rượu. B-Mode và CAP tương hợp trong khi Fibroscan và ARFI không tăng theo độ mỡ CAP.
Case 430: FACIAL EDEMA, Dr PHAN THANH HẢI, Dr LÊ NGỌC VINHhungnguyenthien
Woman 33yo, with history onset one year ago, fever and some red macula appeared at abdominal skin that biopsy result of macula was lipoma. But it is not in stop of progress, a lot of red macula were getting more over 2 legs and upper arms to her right face.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
2. • The prognosis of HCC is deemed poor
unless the cancer is detected and treated
at an early stage. Thus, the assessment of
risk for HCC development is essential in
the management of patients with chronic
liver diseases.
3. HCV infection typically progresses to chronic infection in more than 60% of
patients, and it can lead to cirrhosis in as many as 20% over a 20-year
period. Serum aminotransferase levels reflecting hepatocellular injury can
fluctuate, as does the viral load.
As the disease evolves, hepatocytes are progressively destroyed and replaced
by fibrosis, insidiously leading to the development of bridging fibrosis and
ultimately cirrhosis. The course of any individual patient is affected by
various factors, such as age at onset of infection, sex, co-infection with
other viruses (hepatitis A virus, HBV or HIV), or other medical conditions, as
well as risk behavior, such as alcohol consumption. Interferon-based
treatment has a varying success rate in clearing the virus, The risk of
developing HCC in chronic HCV patients with cirrhosis is as high as 4% per
year. . Although successful treatment with interferon-based regimens is
associated with a lower rate of liver-related complications or mortality, and
perhaps even regression of fibrosis/cirrhosis, patients may still be at risk of
development of HCC, even years after SVR.
4. Lauer and Walker, 2001
Normal
liver
Acute
infection
Chronic
infection
develops
in 80%
Chronic
hepatitis
Cirrhosis
develops
in 20%
Risk of
carcinoma,
1-4%
per year
≤ 20 years
Alcohol use, coinfection
≥ 30 years
Female, young age at infection
Slow
Fast
Rateofprogression
Natural History of HCV Infection:Natural History of HCV Infection:
Individual VariabilityIndividual Variability
5. • Educating patients regarding the natural
history of chronic HCV is one of the most
important things that a physician can do
for a patient with recently diagnosed
chronic HCV.
6. A warning that cirrhosis has developed
and that the risk of complications (such
as hepatocellular carcinoma) has
increased considerably.
7. • In patients with HCV, the risk for HCC increases with the development of
cirrhosis. The risk for HCC in patients with only bridging fibrosis may be <
1% per year. Some patients with HCV who develop HCC in the absence of
cirrhosis may also have occult HBV infection. Patients with HCV are more
likely to present with multiple hepatic tumors than are patients with HBV]
HCV/HBV coinfection, HCV/HIV coinfection, and concomitant diabetes
mellitus increase the risk for HCC. Suppression of viral replication with
antiviral treatments may not eliminate the risk for HCC in patients with HCV
cirrhosis] Routine screening should continue even if a sustained viral
response is attained after antiviral treatment. Cirrhosis of any cause carries
a risk for development of HCC; hemochromatosis, alcoholic liver disease,
nonalcoholic fatty liver disease, autoimmune hepatitis, primary biliary
cirrhosis, and Wilson disease have all been associated. Additional risk
factors for HCC in patients with cirrhosis include male sex, age older than
40 years, past or present obesity, diabetes mellitus, nonalcoholic fatty liver
disease, cigarette smoking, a family history of HCC, exposure to aflatoxin,
and hepatic venous outflow obstruction.
8. • Genetic Risk of Hepatocellular
Carcinoma in Patients With Hepatitis C
Virus
9. • Single nucleotide polymorphisms of
CCND2, RAD23B, GRP78, CEP164,
MDM2, and ALDH2 genes were
significantly associated with development
and recurrence of HCC in patients with
HCV.
10. IL28B minor allele is associated with a
younger age of onset of hepatocellular
carcinoma in patients with chronic
hepatitis C virus infection
11. • All HCV patients should be screened to
exclude cirrhosis by TE if available. Serum
biomarkers can be used in the absence of
TE • HCV patients who were diagnosed
with cirrhosis based on non-invasive
diagnosis should undergo screening for
HCC and PH and do not need
confirmatory liver biopsy
12.
13. • The parameters included are commonly
recorded in clinics, which indicate that the
scoring system could be used routinely in
the clinic. The clinical practice.
14. • Calculation of Laboratory Liver Fibrosis Indices
The following values were obtained through serum sample
analysis: aspartate aminotransferase (AST), alanine
aminotransferase (ALT), gamma-glutamyl
transpeptidase (GGTP), platelet count, and cholesterol.
The APRI [18] was calculated as (AST [IU/L] / upper limit
of normal AST [IU/L]) × 100 / platelet count [109/L]. The
FIB-4 index [19, 20] was calculated as AST [IU/L] × age
[years]/ platelet count [109/L] × ALT [IU/L]1/2. The Forns
index [21] was calculated as 7.811–3.131ln(platelet
count [109/L]) + 0.781ln(GGT [IU/L]) + 3.467.ln(age)–
0.014 (cholesterol [mg/dL]).
15.
16.
17.
18. • TE could be useful to identify patients at
risk of developing HCC.
• high LS value measured by TE is
significantly associated with
• the risk of presence of HCC.
19.
20.
21. • Finally, it has been recently suggested that SS
could predict the occurrence of complications .
Thus the potential of LS values for predicting
clinical outcomes seems to be greater than that
of liver biopsy, probably LS measures ongoing
pathophysiological processes and functions that
a biopsy cannot. Similarly, serum biomarkers
such as FibroTest , ELF ], APRI and FIB-4
[222,331], as well as for models based on
standard laboratory tests] have been shown to
have prognostic value in various chronic liver
diseases.
22. • As we know, SVR of HCV could reduce the risk
of HCC. For the high risk patients who did not
achieve SVR before, we have to do more effort
to eradicate the HCV virus in order to reduce
HCC. In patients who could not achieve SVR or
who are still within high risk category even after
SVR, selection of an intensive HCC surveillance
program is important to early detect HCC,
followed by early treatment which could increase
patients’ survival.
23. • CHC patients who respond to peg-IFN
combination therapy should be followed
even after HCV eradication, and special
attention should focus on those who have
severe liver fibrosis (F3 or F4), those with
low pre-treatment platelet levels
(,150 ラ 109/L) and those who are aged
≥60 years, to detect potentially treatable
HCC.
24. • The most important long-term HCC risk
predictors for chronic hepatitis B patients
are serum levels of HBV DNA, HBsAg and
alanine aminotransferase (ALT), HBeAg
serostatus, HBV genotype, HBV basal
core promoter A1762T/G1764A mutant,
gender, age, family HCC history, habitual
alcohol consumption, and co-infection with
HCV or HIV.
25. The long-term HCC risk predictors for
chronic hepatitis C patients include
increasing age, cirrhosis status, HCV
genotype 1, elevated serum levels of HCV
RNA and ALT and co-infection with HBV.
26. • Role of occult hepatitis B virus infection in chronic
hepatitis C.
In everyday clinical practice,
the detection of anti-hepatitis B core antibody (anti- HBc)
in serum of HBsAg-negative subjects is used as a
surrogate marker to identify patients with OBI.
In patients with chronic hepatitis C (CHC), OBI has been
identified in nearly one-third of these cases.
Considerable data suggest that OBI favors the increase
of liver damage and the development of hepatocellular
carcinoma (HCC) in patients with CHC.
27. • Anti-HBc-positive results on serologic
testing are a marker of high risk for HCC
among patients with HCV-related
cirrhosis. Interferon therapy might be less
effective in preventing HCC among
patients with chronic hepatitis C who are
anti-HBc-positive than in those with
chronic hepatitis C who are anti-HBc-
negative.
28.
29. • MEDIC Researchers Develop Risk
Scores to Prioritize Individuals for
Population-wide Hepatocellular
Carcinoma Screening Using Liver
Ultrasound